# Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

> **NCT03581591** · PHASE3 · COMPLETED · sponsor: **Redwood Dermatology Sciences** · enrollment: 1 (actual)

## Conditions studied

- Hypophosphatemia
- Hypophosphatemic Rickets
- Pain, Chronic

## Interventions

- **BIOLOGICAL:** Burosumab

## Key facts

- **NCT ID:** NCT03581591
- **Lead sponsor:** Redwood Dermatology Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-31
- **Primary completion:** 2019-12-06
- **Final completion:** 2019-12-06
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03581591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03581591, "Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03581591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*